58-Year-Old Man With a Mass in the Larynx

In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.

Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.

In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.

Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.